Page 39 - Hepatology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hepatology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hepatology Today - Breaking & Trending Today

FICCI Flo Kolkata Chapter organised Transforming Lives - an enlightening session on Hepatology

FICCI Flo Kolkata Chapter organised Transforming Lives - an enlightening session on Hepatology
Kolkata, Feb 19 (UNI) FICCI Flo Kolkata chapter has organised Transforming Lives, an informational and in-depth session on the human liver with Dr Rajiv Jalan, Prof. of Hepatology at University College London, and a world-renowned hepatologist.
During the session, he asked the viewers to “think about your liver as your Ji (your best friend), and take care of it”. He also talked about two drugs being developed by his company, which are in the second phase of testing and will be rolled out soon, for liver-centric diseases.
Introducing Dr Rajiv Jalan and Dr Rupali Basu, MD & CEO of Woodland Multispeciality Hospital, Ms Sunira Chamaria, Chairperson, FICCI Flo Kolkata chapter, said, “Liver is not given the importance it deserves.” ....

West Bengal , United States , United Kingdom , City Of , Rajiv Jalan , Manjri Agarwal , Sunira Chamaria , Rupali Basu , Hepatology At University College London , Kolkata Chapter , Transforming Lives , University College London , Woodland Multispeciality Hospital , Senior Vice Chairperson , Damodar Ropeway , Infra Limited , மேற்கு பெங்கல் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ராஜீவ் ஜலான் , மஞ்சிரி அகர்வால் , ரூபாலி பாசு , ஹெபடாலஜி இல் பல்கலைக்கழகம் கல்லூரி லண்டன் , கொல்கத்தா அத்தியாயம் , மாற்றும் உயிர்கள் ,

Discovery of 'Achilles heel' in gut bacteria may lead to targeted therapies for Crohn's disease

Discovery of ‘Achilles heel’ in gut bacteria may lead to targeted therapies for Crohn’s disease
The discovery of an Achilles heel in a type of gut bacteria that causes intestinal inflammation in patients with Crohn s disease may lead to more targeted therapies for the difficult to treat disease, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
In a study published Feb. 3 in
Cell Host and Microbe, the investigators showed that patients with Crohn s disease have an overabundance of a type of gut bacteria called adherent-invasive Escherichia coli (AIEC), which promotes inflammation in the intestine. Their experiments revealed that a metabolite produced by the bacteria interacts with immune system cells in the lining of the intestine, triggering inflammation. Interfering with this process, by either reducing the bacteria s food supply or eliminating a key enzyme in the process relieved gut inflammation in a mouse model of Crohn s disease ....

Weill Cornell , Monica Viladomiu , Ellen Scherl , Maeva Metz , Sloan Kettering , Randy Longman , Emily Henderson , Jill Roberts Center , Division Of Gastroenterology , Jill Roberts Institute For Research , Presbyterian Weill Cornell Medical Center , Weill Cornell Medicine , Cell Host , Inflammatory Bowel Disease , Weill Cornell Medical , Chun Jun Guo , Gretchen Diehl , Memorial Sloan Kettering , Kenneth Simpson , Jill Roberts Institute , Weill Cornell Medicine Graduate School , Medical Sciences , Inflammatory Bowel , Crohn 39s Disease , Immune System , Mouse Model ,

Cadila Healthcare rises after USFDA grants orphan drug designation for Saroglitazar Mg

Read more about Cadila Healthcare rises after USFDA grants orphan drug designation for Saroglitazar Mg on Business Standard. Cadila Healthcare rose 0.69% to Rs 465.40 after the company was granted orphan drug designation by the US drug regulator for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC). ....

Cadila Healthcare , Primary Biliary Cholangitis , Fast Track Designation , Capital Market , Medical Specialties , Companies Based In Ahmedabad , Autoimmune Diseases , Cadila Pharmaceuticals , Ascending Cholangitis , Orphan Drug , Secondary Sclerosing Cholangitis , Primary Biliary , காடிலா சுகாதாரம் , வேகமாக டிராக் பதவி , மூலதனம் சந்தை , மருத்துவ சிறப்பு , நிறுவனங்கள் அடிப்படையிலானது இல் அஹமதாபாத் , ஆட்டோ இம்யூன் நோய்கள் , காடிலா மருந்துகள் , ஆர்ஃபந் மருந்து , ப்ரைமரீ பிலியரி ,

Zydus receives USFDA 'Orphan Drug Designation' for Saroglitazar Mg

Zydus announced that United States Food and Drug Administration (USFDA) has granted Orphan Drug Designation (ODD) to
Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC).
Orphan drug
designation provides eligibility for certain development incentives, including tax credits for qualified
clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon
FDA approval.
This follows the grant of Fast Track Designation by the USFDA to Saroglitazar Mg
for PBC in December 2020.
Saroglitazar Mg is a potent and selective peroxisome proliferator-activated receptor alpha and gamma
dual agonist. Results of PHASE 2, prospective multicentre randomized double-blind, placebo
controlled study to evaluate the safety, tolerability and efficacy of Saroglitazar Mg in patients with ....

United States , Drug Administration , United States Food , Orphan Drug Designation , Primary Biliary Cholangitis , Fast Track Designation , Liver Meeting , Annual Meeting , American Association , Liver Diseases , Capital Market , Medical Specialties , Clinical Medicine , Autoimmune Diseases , Orphan Drug , Ascending Cholangitis , Obeticholic Acid , Ursodeoxycholic Acid , American Association For The Study Of , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது மாநிலங்களில் உணவு , ஆர்ஃபந் மருந்து பதவி , வேகமாக டிராக் பதவி , கல்லீரல் சந்தித்தல் , ஆண்டு சந்தித்தல் , அமெரிக்கன் சங்கம் ,

Researchers design armored immune cells to attack recurring cancer in liver transplant patients

Researchers design armored immune cells to attack recurring cancer in liver transplant patients
Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant drugs patients take to avoid organ rejection. The findings were published in the journal
Hepatology.
Hepatocellular carcinoma is the most common type of primary liver cancer and the sixth most common cancer worldwide. It often develops in people with chronic liver disease following hepatitis B infection.
A common treatment for hepatocellular carcinoma is to completely remove the liver and replace it with a healthy one from a donor. However, hepatitis B-related hepatocellular carcinoma can recur in some patients following transplantation. To kill the cancer, doctors can inject immune cells, called T cells, which are specially designed to target hepatitis ....

Patrick Casey , Antonio Bertoletti , Emily Henderson , Dean For Research , Infectious Diseases Programme , Professor Antonio Bertoletti , Emerging Infectious Diseases , Prof Bertoletti , Senior Vice Dean , Hepatitis B , Hepatocellular Carcinoma , Liver Cancer , Liver Disease , Liver Transplant , Medical School , பேட்ரிக் வழக்கு , எமிலி ஹென்டர்சன் , டீன் க்கு ஆராய்ச்சி , தொற்று நோய்கள் ப்ரோக்ராம் , வளர்ந்து வருகிறது தொற்று நோய்கள் , மூத்தவர் துணை டீன் , கல்லீரல் புற்றுநோய் , கல்லீரல் நோய் , கல்லீரல் மாற்று , மருத்துவ பள்ளி ,